nanoTherics Wins R&D Grant from Advantage West Midlands to Further Augment Gene Transfection Product Portfolio
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
nanoTherics, a scientific medical research devices company, has announced that it has been awarded a Research & Development (R&D) Grant from the regional development agency Advantage West Midlands (AWM).
The grant will enable the Company to progress development of additional novel gene transfection technologies to augment the Company’s existing product portfolio which already offers significant advantages over other methodologies on the market.
nanoTherics’s primary business is supply of scientific devices and associated products to research laboratories in the pharmaceutical and biotechnology industries as well as academia. The Company’s products apply a patent-pending technology using nanoparticles and magnetic fields to facilitate enhanced delivery of biomolecules, such as DNA, into living cells. The medium to long-term opportunity for this approach relates to effective non-viral gene therapy.
Dr Linda Cammish, Chief Executive Officer, said, “We are very pleased to have been successful in obtaining this grant which provides further external validation of the value of the systems we are developing to offer improvements in transfection technologies to researchers in the growing life science sector. The due diligence that is part of the application process and the rigorous nature of the AWM grant conditions means that our success is a fantastic endorsement”.
She added, “The grant will enable us to ensure our technologies will continue to offer improvements and significant advantages to end-users of our systems. We aim to introduce a range of products which will shortly be initiated with the launch of the magnefect-nano, a flexible device which provides up to 1000-fold better transfection efficiency than cationic lipid agents for short transfection times.
The grant will enable the Company to progress development of additional novel gene transfection technologies to augment the Company’s existing product portfolio which already offers significant advantages over other methodologies on the market.
nanoTherics’s primary business is supply of scientific devices and associated products to research laboratories in the pharmaceutical and biotechnology industries as well as academia. The Company’s products apply a patent-pending technology using nanoparticles and magnetic fields to facilitate enhanced delivery of biomolecules, such as DNA, into living cells. The medium to long-term opportunity for this approach relates to effective non-viral gene therapy.
Dr Linda Cammish, Chief Executive Officer, said, “We are very pleased to have been successful in obtaining this grant which provides further external validation of the value of the systems we are developing to offer improvements in transfection technologies to researchers in the growing life science sector. The due diligence that is part of the application process and the rigorous nature of the AWM grant conditions means that our success is a fantastic endorsement”.
She added, “The grant will enable us to ensure our technologies will continue to offer improvements and significant advantages to end-users of our systems. We aim to introduce a range of products which will shortly be initiated with the launch of the magnefect-nano, a flexible device which provides up to 1000-fold better transfection efficiency than cationic lipid agents for short transfection times.
